Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

Authenticated data presented in the Respiratory Drugs market report is based on findings of extensive primary and secondary research ...

was superior to salmeterol (long-acting inhaled β 2 agonist medication) in preventing COPD exacerbations. In this randomized, controlled, multicenter, international trial, 7376 patients with ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the 'Company'), a global ...

Cholinergic drugs (acetylcholine and methacholine ... Tiotropium, the first-choice long-acting bronchodilator in COPD, has been studied in severe asthmatics and in COPD patients with a history ...

Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.

Headquartered in Switzerland, Windward Bio is a clinical-stage drug development company ... windward-bio-launch-to-advance-long-acting-treatments-for-asthma-and-copd-302348011.html ...

FDA approved bronchodilator carmoterol and d-methamphetamine found in 23 drug tests from horses running at Lone Star Park ...

Windward Bio's lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting ... and chronic obstructive pulmonary disease ...